Ken Londoner is the Executive Chairman & Founder, BioSig Technologies, Inc. He is famous for working on and commercializing a new system to more accurately treat patients suffering from Atrial Fibrillation, or irregular heartbeats.
Ken Londoner was born on August 3, 1968 in Westport, CA. At the age of 25 he moved to New York where he worked with many companies. At the age of 30 he was asked to become a professor at the Columbia University. He is passionate about tennis, poker, golfing, skiing, and handling finance for big businesses.
Londoner has studied at the Lafayette College from 1986 to 1989, where he acquired a degree in economics and finance. Later, in 1992 he enrolled at the NYU. Ken Londoner has a Masters Degree in Business Administration (MBA) from New York University Stern School of Business with a dual major in finance and management. In more recent years, Ken has been active as a Visiting Professor at the Columbia University in the City of New York. After graduating from Lafayette College and obtaining MBA from NYU’s Stern School of Business, Ken Londoner started building his professional career, initially by working in the investment sector.
In September 1989 he got his first job and was hired as a Financial and Equities Accountant of State Street Bank and Trust, Inc. After that he signed a contract with New Cardio Inc, one of the biggest and leading healthcare companies. He stayed there for over 7 years, initially starting as a research analyst, but ended up as a Senior Vice President and Investment Officer. This skilled entrepreneur also co-founded Safe Ports Holdings in Charleston, South Carolina, a port security and logistics company that built and sold an inland port development project to Dubai Ports World. Ken Londoner founded and managed Arrowpoint Capital Management, assisted InspireMD, and was a Founding Investor of Carolina Linkages Inc. From 1996 to July 2005 he served as Chief Executive Officer & General Partner at Aduromed Corporation. Nowadays, Ken Londoner serves as Executive Chairman of BioSig Technologies, Inc. It is a privately held medical technology company formed in 2009, which is working on developing and commercializing a new system to accurately treat patients suffering from Atrial Fibrillation. In addition to that he is also Managing Partner of Endicott Management Partners, LLC, a private investment company focused on medical technology and consumer-related companies.